

17th November, 2015

To,
Department of Corporate Services
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

Ref. : Scrip Code No. : 532526

Sub.: Clarification

Dear Sir,


With reference to your letter No. L/DOSS/ONL/RV/JP/2015-16/148 dated 17th November, 2015, we would like to clarify on the same as under:

1. The Company has not received any USFDA warnings or any communication whatsoever due to Clovis Issue,
2. We are not privy to any information of our customers due to regulatory issue,
3. Recent news item which appeared in the Website-www.moneycontrol.com/ET Now/CNBC dated 17-Nov-2015 are basically with related to Clovis Oncology only and it has not relevance with our Company,
4. The Company has always been fully compliant and inform to Stock exchanges of such information which is required under listing agreement as well as Clause 36 of the Listing Agreement.

Kindly take note of the same.

Thanking You,

Yours faithfully,
For Dishman Pharmaceuticals and Chemicals Ltd.



Tushar D. Shah
Company Secretary

Dishman Pharmaceuticals and Chemicals Limited

Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India.

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

Government Recognised Export House

CIN NO L24230GJ1983PLC006329